

Accepted Manuscript

Shear-induced Hydrodynamic Cavitation as a tool for Pharmaceutical Micropollutants removal from urban wastewater

Mojca Zupanc, Tina Kosjek, Martin Petkovšek, Matevž Dular, Boris Kompare, Brane Širok, Marjeta Stražar, Ester Heath


PII: S1350-4177(13)00256-3
DOI: <http://dx.doi.org/10.1016/j.ultsonch.2013.10.025>
Reference: ULTSON 2427

To appear in: *Ultrasonics Sonochemistry*

Received Date: 20 June 2013
Revised Date: 23 October 2013
Accepted Date: 27 October 2013

Please cite this article as: M. Zupanc, T. Kosjek, M. Petkovšek, M. Dular, B. Kompare, B. Širok, M. Stražar, E. Heath, Shear-induced Hydrodynamic Cavitation as a tool for Pharmaceutical Micropollutants removal from urban wastewater, *Ultrasonics Sonochemistry* (2013), doi: <http://dx.doi.org/10.1016/j.ultsonch.2013.10.025>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **SHEAR-INDUCED HYDRODYNAMIC CAVITATION AS A TOOL FOR PHARMACEUTICAL**
2 **MICROPOLLUTANTS REMOVAL FROM URBAN WASTEWATER**

3
4 Mojca Zupanc^{a,b,c}, Tina Kosjek^a, Martin Petkovšek^d, Matevž Dular^d, Boris Kompare^e, Brane
5 Širok^d, Marjeta Stražar^f and Ester Heath^{a,b}

6
7 ^a Jožef Stefan Institute, Department of Environmental Sciences, Ljubljana, Slovenia

8 ^b Jožef Stefan International Postgraduate School, Ljubljana, Slovenia

9 ^c Ecological Engineering Institute Ltd, Maribor, Slovenia

10 ^d Faculty of Mechanical Engineering, University of Ljubljana, Ljubljana, Slovenia

11 ^e Faculty of Civil and Geodetic Engineering, University of Ljubljana, Ljubljana, Slovenia

12 ^f JP CCN Domzale-Kamnik d.o.o. (Domzale-Kamnik WWTP), Domzale, Slovenia

13
14
15 **ABSTRACT**

16
17 In this study, the removal of clofibric acid, ibuprofen, naproxen, ketoprofen, carbamazepine
18 and diclofenac residues from wastewater, using a novel shear-induced cavitation generator
19 has been systematically studied. The effects of temperature, cavitation time and H₂O₂ dose
20 on removal efficiency were investigated. Optimisation (50 °C; 15 min; 340 mg L⁻¹ of added
21 H₂O₂) resulted in removal efficiencies of 47 – 86 % in spiked deionised water samples.
22 Treatment of actual wastewater effluents revealed that although matrix composition reduces
23 removal efficiency, this effect can be compensated for by increasing H₂O₂ dose (3.4 g L⁻¹)
24 and prolonging cavitation time (30 min). Hydrodynamic cavitation has also been investigated
25 as either a pre- or a post-treatment step to biological treatment. The results revealed a higher
26 overall removal efficiency of recalcitrant diclofenac and carbamazepine, when hydrodynamic
27 cavitation was used prior to as compared to post biological treatment i.e., 54 and 67 % as
28 compared to 39 and 56%, respectively. This is an important finding since diclofenac is
29 considered as a priority substance to be included in the EU Water Framework Directive.

30
31
32 *Highlights*

- 33
34
- 35 • A novel shear-induced hydrodynamic cavitation is employed to study the removal of
36 pharmaceuticals from wastewaters.
 - 37 • Shear-induced cavitation resulted in higher removal efficiencies when compared to
38 Venturi design.
 - 39 • We obtained removal efficiencies of up to 86 % in deionised water and up to 79 % in
40 wastewater effluent.
 - 41 • Hydrodynamic cavitation as a pre-treatment removed the highest amounts of
42 carbamazepine and diclofenac.
- 43
44
45

46 *Keywords:* Pharmaceutical; Removal; Hydrodynamic cavitation; Wastewater

47
48

49 **Abbreviations**

50

51	AOP	advanced oxidation process
52	HC	hydrodynamic cavitation
53	WW	wastewater
54	CLA	clofibric acid
55	IB	ibuprofen
56	NP	naproxen
57	KP	ketoprofen
58	DF	diclofenac
59	CBZ	carbamazepine
60	MTBSTFA	N-(t-butyltrimethylsilyl)-N-methyltrifluoroacetamid
61	WWTP	wastewater treatment plant
62	HCG	hydrodynamic cavitation generator
63	DW	deionised water
64	IT	increasing temperature
65	CT	constant temperature
66	TOC	total organic carbon
67	HRT	hydraulic retention time
68	LOD	limit of detection
69	SPE	solid phase extraction
70	GC-MS	gas chromatography-mass spectrometry
71	EE	energy efficiency
72	EC	energy consumption
73	WFD	Water Framework Directive

74

75

76 1 INTRODUCTION

77

78 Pharmaceuticals are an important and indispensable element of modern life but parallel to
79 the continuous rise in their consumption, is the increasing burden on the environment posed
80 by pharmaceutical residues. The main sources of these residues are wastewaters that even
81 after conventional (biological) treatment still contain pharmacologically active compounds.
82 The European Commission recently issued a Proposal for a Directive (COM(2011)876) [1]
83 amending the European Union Water Framework Directives 2000/60/EC [2] and
84 2008/105/EC [3], where amongst the proposed 15 additional priority substances, for the first
85 time are pharmaceutical compounds, one of which is diclofenac.

86

87 Biological wastewater treatment has in many cases proven unsatisfactory for eliminating
88 recalcitrant pharmaceuticals like carbamazepine [4-5], diclofenac [6] and clofibrac acid [7]. To
89 prevent these compounds entering the aquatic environment, where they can potentially
90 induce toxic effects [8-10], alternative non-biological treatments are being investigated. For
91 example various oxidation methods, collectively referred to as advanced oxidation processes
92 (AOPs), have been proposed [11-16]. They are characterized by the *in situ* formation of
93 highly oxidative hydroxyl ($\cdot\text{OH}$) radicals, which with an oxidation potential of 2.80 V are
94 capable of non-selectively attacking structurally diverse organic micropollutants with rate
95 constants of $10^6 - 10^9 \text{ M}^{-1} \text{ s}^{-1}$ [11], [17].

96

97 One such promising AOP is cavitation. The phenomenon of hydrodynamic cavitation (HC)
98 occurs when a drop in pressure, due to velocity variations created by the geometry of a
99 flowing system, results in the formation of bubbles (cavities) [12], [18-19]. When these
100 cavities implode, extreme energies that can drive chemical and mechanical effects are
101 released. For instance, localised areas of high temperature and pressure ("hotspots") result
102 in the homolytic cleavage of water molecules inside the cavities, generating $\cdot\text{OH}$ radicals
103 [18], [20-21]. For these reasons the cavitation phenomenon has been the focus of scientific
104 attention as a possible process for removing various organic compounds [20-22]. Breakdown
105 during cavitation can occur at three locations: i) in the gas phase i.e., inside the bubble,
106 where thermolytic decomposition of volatile compounds and $\cdot\text{OH}$ formation take place; ii) at
107 the gas-liquid interface, where degradation of non-volatile and hydrophobic compounds can
108 occur, and iii) in the liquid bulk phase, where degradation of non-volatile and hydrophilic
109 compounds can take place [19], [23]. Since only a small amount of radicals reach the liquid
110 bulk phase, since they either react between themselves or with any oxidizable compound in
111 the vicinity, removal of organic compounds depends on their chemical nature [19]. To
112 intensify this process, the addition of external oxidants e.g. H_2O_2 as a source of radicals is
113 also an option [22].

114

115 Published studies investigating HC as a tool for disinfection [24], cell disruption [25],
116 preparation of stable nano-suspensions [26] and the removal of various organic compounds
117 from wastewater (WW) [20], [22], [27-29] are available, but data about the efficiency of HC
118 for the removal of pharmaceutical residues from WW are scarce. To our knowledge only two
119 studies have been published on this topic; Brauetigam and co-workers [21] investigated the
120 removal of carbamazepine by hydrodynamic and acoustic cavitation, while Zupanc and co-
121 workers [30] studied the removal of clofibrac acid, ibuprofen, naproxen, ketoprofen,
122 carbamazepine and diclofenac by hydrodynamic cavitation alone.

123

124 Hydrodynamic cavitation is usually generated either by high-velocity passage of the liquid
125 through a constriction such as an orifice plate or Venturi pipe, the use of high-speed
126 homogenizers, devices based on the rotor-stator principle or by a rotating propeller blade
127 [27-28]. This study is a continuation of this group's previous research where a Venturi
128 constriction was used as a means of cavitation. In this study a novel design approach is
129 taken that uses two facing counter-rotating discs to generate shear-induced HC. When
130 compared to the Venturi geometry [30], cavitation in the present design extends over a larger

131 volume and pressure recovers more rapidly, which leads to more aggressive cavitation
132 resulting in the formation of more radicals [31].

133

134 In Zupanc and co-worker's study [30] the authors focused on the removal of clofibrac acid
135 (CLA), ibuprofen (IB), naproxen (NP), ketoprofen (KP), carbamazepine (CBZ) and diclofenac
136 (DF) in deionised water and synthetic wastewater effluent using Venturi geometry to
137 generate HC. In this study the removal of pharmaceuticals by shear-induced HC is
138 investigated with the aim of improving the removal of pharmaceuticals from wastewaters,
139 testing the efficiency of the system using real WW samples, and determining whether or not
140 HC would be more efficient as a pre- or post-treatment to biological removal.

141

142

143 2 MATERIALS AND METHODS

144

145 2.1 Standards and chemicals

146

147 All six investigated compounds were provided either by Sigma–Aldrich (Steinheim, Germany)
148 or Acros Organics (New Jersey, USA) and were of high purity ($\geq 97\%$). CDN Isotopes
149 (Quebec, Canada) supplied isotopically labelled internal standards (\pm)-ibuprofen- d_3 (α -
150 methyl- d_3), carbamazepine- d_{10} (rings- d_{10}) and (\pm)-ketoprofen (α -methyl- d_3). N-(t-
151 butyldimethylsilyl)-N-methyltrifluoroacetamid (MTBSTFA), used for derivatisation, was
152 supplied by Acros Organics (New Jersey, USA). Analytical grade solvents acetonitrile
153 (preparation of standard solutions), methanol and ethyl acetate, were supplied by J.T. Baker
154 (Deventer, the Netherlands). Analytical grade chemicals used were 37 % hydrochloric acid
155 (AppliChem, Darmstadt, Germany) and 30 % hydrogen peroxide (Merck, Darmstadt,
156 Germany). Potassium dichromate was purchased from Riedel-de-Haën, Hannover,
157 Germany.

158

159

160 2.2 Hydrodynamic cavitation set-up

161

162 In this study an open-loop experimental set-up for shear-induced HC generation was
163 designed (Figure 1). An open-loop design was chosen in order to establish conditions
164 comparable to an actual wastewater treatment plant (WWTP). Before each experiment, 2.5 L
165 of sample was introduced into the feeding reservoir (1) and allowed to fill the hydrodynamic
166 cavitation generator (HCG) chamber (2). Flow and pressure adjustments inside the HCG,
167 were made possible by adjusting the valves (3) situated prior to and aft of the chamber. The
168 static pressure inside the HCG was set to 100 kPa and monitored using a pressure
169 transmitter (4). During the experiments the sample was circulated through the device using a
170 small centrifugal pump (5). A cooling system was used to maintain a constant temperature
171 (6) and monitored using a resistance temperature detector (Fluke Corporation, Washington,
172 USA) (7). Installation of the cooling system reduced the flow rate in the system from approx.
173 10 L min^{-1} to 3.5 L min^{-1} .

174

175 *** Insert Figure 1 here ***

176

177 **Fig. 1.** Schematic presentation of the open-loop HC set-up (1: feeding reservoir, 2: HCG
178 chamber, 3: control valves, 4: pressure transmitter, 5: centrifugal pump, 6: cooling system, 7:
179 resistance temperature detector).

180

181 The HCG (Figure 2) consists of two facing rotors (Fig. 2: R1 and R2) made of stainless steel
182 with a 0.8 mm gap between them (Fig. 2: A). The housing of the HCG chamber is made of
183 plexi-glass. The rotors have a diameter of 90 mm and are spun at 2800 rpm (reaching local
184 velocities of up to 26 m s^{-1}) by two electrical motors (Fig. 2: EM1 and EM2). To avoid
185 resonance, the rotors differ slightly in their design; rotor R1 has 12 grooves and teeth with an

186 8° inclination (Fig. 2: a), while R2 has 11 grooves and level angled teeth. The grooves on
187 both rotors are 7 mm deep (Fig. 2: b) and 10 mm wide (Fig. 2: c). When a tooth and a groove
188 of R1 are aligned with a tooth and a groove of R2 (Fig. 2: dashed rectangle in the centre of
189 the figure), the gap between the opposing teeth resembles the Venturi geometry. By spinning
190 the rotors in opposite directions, zones of low static pressure form, sufficient to induce the
191 cavitation phenomenon (Fig. 2: B). Shear-induced cavitation is, therefore, a consequence of
192 the opposite movement of the two shear layers that form between the two rotors.

193
194 ***** Insert Figure 2 here *****

195
196 **Fig. 2.** Design of the HCG (R1: rotor with 12 grooves, R2: rotor with 11 grooves, A: 0.8 mm
197 gap, EM1: electrical motor, EM2: electrical motor, a: 8° inclination, b: 7 mm depth, c: 10 mm
198 width, B: cavitation zones).

199
200 Cavitation was visually observed using a high speed camera. In addition, high frequency
201 pressure oscillations, measured with a hydrophone, enabled evaluation of the true extent and
202 aggressiveness of cavitation. Design and operation of the HC chamber set-up is explained in
203 greater detail elsewhere [32].

204 205 206 **2.3 Experimental design**

207
208 The efficiency of the HCG for removing pharmaceutical residues was evaluated in aqueous
209 matrices differing in the amount and diversity of organic substances: deionised water (DW)
210 and WWTP influents and effluents. The DW experiments were performed using a fixed
211 concentration of pharmaceuticals ($1 \mu\text{g L}^{-1}$) and the efficiency of HC was investigated under
212 both increasing temperature (IT) and constant temperature (CT). During the IT experiments,
213 sample temperature rose due to the dissipation of hydraulic energy as heat. The final
214 temperature was allowed to reach 68 °C before the experiments were halted. In the case of
215 CT, the temperature of the sample was maintained at a desired level ($\pm 1 \text{ }^\circ\text{C}$) during the
216 experiments using a heating/cooling system. The optimal operating temperature was then
217 determined and all further experiments involving WW samples were performed under CT. HC
218 was then integrated as a pre- and post-treatment step in a laboratory scale biological WW
219 treatment. As a biological step, an attached-growth biomass process was chosen. A 4 L
220 aerated laboratory scale bioreactor filled with Kaldnes K1 carriers, occupying approx. 30% of
221 the working volume, was used. The design and operation of the bioreactor is described in full
222 in [30]. In experiments involving WW samples besides pharmaceuticals removal efficiency
223 additional parameters, important for WW treatment, were also measured. Mineralisation of
224 organic compounds during experiments was determined in terms of total organic carbon
225 (TOC) removal, and oxidation of nitrogen species was measured by determining
226 concentrations of $\text{NH}_4\text{-N}$ and $\text{NO}_3\text{-N}$ before and after experiments. Table 1 gives an overview
227 of the experimental conditions.

228 229 **Table 1**

230 Experimental conditions.

231
232 ***** Insert Table 1 here *****

233
234 To confirm the hypothesis that removal of pharmaceuticals occurs only when a suitable
235 combination of temperature, cavitation and H_2O_2 exists (Table 2), a series of control
236 experiments were designed to:

- 237
- 238 - confirm that removal of pharmaceuticals does not occur only because of elevated
239 temperature (Exp 6);

- 240 - investigate whether cavitation and elevated temperature are sufficient for
241 pharmaceuticals removal (Exp 7);
242 - confirm that the formation of $\cdot\text{OH}$ from H_2O_2 is due to the catalytic effect of HC and not
243 just H_2O_2 addition and temperature elevation is mainly responsible for removal of
244 pharmaceuticals (Exp 8);
245 -
246 ther investigate the role $\cdot\text{OH}$ plays, 1-butanol was added to the cavitating sample to
247 scavenge radicals formed during HC from H_2O_2 (Exp 9).
248

249 The results of control experiments were compared to results obtained with a combination of
250 all three investigated operating parameters (Exp 10). In the case of Exp 6 and Exp 8 the
251 longest investigated cavitation time was 30 minutes.
252

253 **Table 2**

254 Experimental conditions in control experiments.

255 *** Insert Table 2 here ***
256
257
258

259 **2.4 Sample collection, analytical procedures and method validation**

260
261 A series of WW samples were obtained from an urban WWTP, servicing a population of
262 360.000 and treating approx. 80.000 m^3 of WW per day both mechanically and biologically.
263 Grab samples of WW influent and effluent were sampled without taking into account WWTP
264 hydraulic retention time (HRT). After collection, the samples were transported at 4 °C to the
265 laboratory and stored at -18 °C prior to analysis. The concentrations of IB, NP, KP, CBZ, and
266 DF in the WW samples were between 360 to 6330 ng L^{-1} in the influent samples. Clofibrac
267 acid was not detected, which was expected, since its parent drugs clofibrate, etofibrate and
268 etofylline clofibrate used as blood lipid regulators are not registered for use in Slovenia.
269 Therefore CLA was spiked (approx. 1 $\mu\text{g L}^{-1}$) into the WW influent samples. In addition, since
270 the concentrations of pharmaceuticals were below the limit of detection (LOD) in the WW
271 effluent, a mixture of pharmaceuticals was added (approx. 1 $\mu\text{g L}^{-1}$).
272

273 Analysis was performed according to the method described by Zupanc and co-workers [30].
274 Briefly, samples were filtered (0.45 μm), acidified to pH 2-3 and then spiked with the internal
275 standards. Oasis[®] HLB cartridges were used for solid phase extraction (SPE). MTBSTFA
276 was used to derivatise the samples prior to analysis by gas chromatography-mass
277 spectrometry (GC-MS).
278

279 Both TOC and nitrogen species ($\text{NH}_4\text{-N}$, $\text{NO}_3\text{-N}$) were determined using LCK 386, LCK 303,
280 LCK 340 and LCK 339 cuvette tests and a DR/2800 spectrophotometer (Hach-Lange,
281 Düsseldorf, Germany). Dissolved oxygen concentrations and temperature were measured
282 simultaneously using a HQ30d probe (Hach, Düsseldorf, Germany) and pH was determined
283 using a pH meter (Thermo Fisher Scientific, Waltham, USA). The amount of attached
284 biomass and suspended solids in the bioreactor was determined according to the method
285 described in Zupanc and co-workers [30].
286

287 Method validation parameters such as SPE efficiency, LOD and linearity were determined in
288 DW and in synthetic WW effluent from the lab-scale bioreactor [30]. The SPE efficiency was
289 performed at concentrations of 1 $\mu\text{g L}^{-1}$ and ranged from 81 – 95 %. Limits of detection,
290 calculated as 3-times the standard deviation of the baseline of six blank samples, ranged
291 from 0.4 to 3.7 ng L^{-1} , while linearity was determined by regression analysis ($r^2 \geq 0.98$).
292 Results are presented in Supplementary data Suppl.1.
293
294

3 RESULTS AND DISCUSSION

3.1 Removal of pharmaceuticals by HC in deionised water

3.1.1 Increasing temperature (IT) experiments

During these experiments the temperature of the samples during HCG operation increased from 20 to 68 °C within 26 min (Exp 1, Exp 2 and Exp 3) and from 20 to 55 °C within 15 min (Exp 4 and Exp 5). A temperature of 68 °C was chosen as the upper operating temperature limit to secure the durability of materials and seals used in the HCG chamber.

Figure 3 reveals the low removal of all the tested pharmaceuticals during 26 min of cavitation with no additional H₂O₂ (Exp 1), whereas ≥ 94 % removal was observed with the addition of 6.8 g L⁻¹ H₂O₂ (Exp 2). No significant reduction in removal was observed in Exp 3 (26 min, 3.4 g L⁻¹ of H₂O₂) and Exp 4 (15 min, 6.8 g L⁻¹ of H₂O₂). Only when both the cavitation time and the amount of added H₂O₂ were reduced i.e., 15 min, 3.4 g L⁻¹ of H₂O₂ (Exp 5), did the removal of the pharmaceuticals reduce significantly. The most significant decrease was observed in the case of CLA (> 50 percentage points). These results show that both cavitation time and H₂O₂ affect the removal of pharmaceuticals and confirm previous findings using the Venturi geometry [30]. In comparison the use of shear-induced cavitation (Exp 2) resulted in significantly higher and more consistent removal efficiencies for all tested pharmaceuticals. The main differences between the Venturi geometry and shear-induced cavitation were observed in the case of CLA, IB and KP, where removal was 42 – 49 percentage points higher. This is especially important in the case of biorecalcitrant CLA. The reasons for the improved removal efficiencies we believe are: (i) the volume where cavitation occurs is greater in the present design than in the Venturi geometry, hence pharmaceuticals are more likely to be exposed to aggressive cavitation conditions, and (ii) a rapid pressure recovery in the present design means that shear cavitation is significantly more aggressive than the cavitation occurring behind an obstruction resulting in higher local temperatures and in the amount of free radicals formed [31].

*** Insert Figure 3 here ***

Fig. 3: Removal of pharmaceuticals with increasing temperature (IT) experiments (n = number of experiments).

3.1.2 Constant temperature (CT) experiments

INFLUENCE OF THE OPERATING TEMPERATURE

The influence of temperature on the elimination of different organic compounds by HC has been investigated in numerous studies [20-22], [29]. Wang and Zang [29] found that an increase from 30 to 40 °C augmented the degradation of alachlor, while increasing the temperature to 60 °C resulted in decreased degradation. Patil and Gogate [22] concluded that increasing the temperature from 32 to 39 °C had no effect on methyl parathion degradation. Joshi and Gogate [20] observed a decrease in the degradation of dichlorvos when increasing the operating temperature from 31 to 39 °C. Contrary to our results, a study by Brautegam and co-workers [21] on CBZ degradation using a combination of hydrodynamic and acoustic cavitation found that the temperature of 25 °C resulted in the highest degradation, which then decreased slightly when the temperature was increased to 35 °C. All these studies suggest that an optimal operating temperature needs to be determined for a specific system in order to achieve the highest HC efficiency and that elimination depends on the investigated compound [12].

348 Therefore the effect of temperature on removal efficiency was investigated. Experiments
349 were performed with a cavitation time of 15 min and a H₂O₂ dose of 3.4 g L⁻¹ (Exp 5). Figure
350 4 shows how operating temperature affects the removal of the compounds tested. Where
351 depicted with error bars, experiments were performed in triplicate. In all cases the standard
352 deviation was < 8 %.

353

354 *** Insert Figure 4 here ***

355

356 **Fig. 4.** Effect of the operating temperature on removal of investigated pharmaceuticals with
357 3.4 g L⁻¹ H₂O₂ dose and 15 min cavitation time (n = number of experiments).

358

359 According to literature data [12], lower bulk phase temperatures are generally favourable for
360 the cavitation process to yield higher efficiencies, but this was not the case in this
361 investigation. Experiments at 20 and 30 °C yielded the same results as those at 40 °C (data
362 not shown), while at 40 to 50 °C removal efficiencies were higher (Figure 4). At 60 °C
363 removal was further improved, with the exception of NP and KP, where no statistically
364 significant difference was observed. Further increases in temperature (68 °C) resulted in a
365 decrease in removal efficiency. According to Vassilakis and co-workers [33] and Wang and
366 Zhang [29], increasing the temperature can be beneficial up to a certain point, but as water
367 vapour fills the cavitation bubbles a cushioning effect on cavitation collapse predominates
368 reducing the effectiveness of the HC. This explains why removal efficiency increases up to
369 60 °C, but then decreases with further temperature increase. This effect was most obvious in
370 case of CLA, CBZ and DF. Even though the highest removal was achieved at 60 °C, we
371 concluded that the difference between removal at 50 and 60 °C is not significant, therefore
372 further testing was performed at 50 °C. At this temperature the removal efficiencies for CLA,
373 IB, NP, KP, CBZ and DF were 48, 60, 83, 66, 72 and 82 %, respectively.

374

375 INFLUENCE OF OPERATING TIME

376 The effect of cavitation time was investigated at 5 min intervals from 5 to 30 min at the
377 optimal operating temperature of 50 °C and 3.4 g L⁻¹ of H₂O₂. The results (see
378 Supplementary data Suppl. 2) show that for the majority of investigated pharmaceuticals no
379 significant difference between tested values exists. A cavitation time of 15 min was selected
380 for further experiments.

381

382 INFLUENCE OF H₂O₂ DOSE

383 It is reported that H₂O₂ dissociates into [•]OH under cavitation conditions [20-21], [29] resulting
384 in additional chemical oxidation, thus intensifying HC efficiency. To investigate this effect
385 different doses of H₂O₂ (0 – 6.8 g L⁻¹) were tested. Figure 5 shows how increasing the H₂O₂
386 dose positively influences the removal of pharmaceuticals, but only up to a point. For most
387 pharmaceuticals 1.7 g L⁻¹ of H₂O₂ was optimal with the exception of DF, which required the
388 addition of 3.4 g L⁻¹ of H₂O₂. At the optimal dose removal efficiencies were from 55 – 93 %,
389 but when the amount of added H₂O₂ was increased to 6.8 g L⁻¹, removal efficiency reduced
390 for more than 15 percentage points. This is because H₂O₂, when in excess acts as a
391 scavenger of [•]OH. These observations confirm those of Joshi and Gogate [20] and Zupanc
392 and co-workers [30].

393

394 *** Insert Figure 5 here ***

395

396 **Fig. 5.** Effect of H₂O₂ dose on removal efficiency of investigated pharmaceuticals (1 µg L⁻¹) at
397 50 °C with a 15 min cavitation time (n = number of experiments).

398

399 Since the difference between the removal efficiency obtained at 0.34 and 1.7 g L⁻¹ of H₂O₂
400 was not significant for most of the investigated compounds, a concentration of 0.34 g L⁻¹ was
401 selected. When compared to results achieved using the Venturi geometry [30], comparable

402 or higher removals of all pharmaceuticals with much lower H_2O_2 dose and reduced cavitation
403 time (i.e. 0.34 g L^{-1} and 15 min) were obtained.

404

405 3.1.3 Control experiments

406

407 Figure 6 shows that pharmaceuticals are not removed at elevated temperatures only (Exp 6).
408 Exp 7 shows that cavitation and elevated temperature do not yield the highest removals.
409 Furthermore, Exp 8 and 9 show how $\cdot\text{OH}$ radicals formed during cavitation and not just H_2O_2
410 and elevated temperature are primarily responsible for their removal. As evident from Figure
411 6, 1-butanol totally inhibited the removal of CBZ and DF. The removal of CLA, IB and KP did
412 not exceed 9 %, whereas NP removal was 29 %. When these results are compared to
413 results obtained in Exp 10, the hypothesis that only a combination of all three parameters i.e.
414 temperature, cavitation and H_2O_2 yields the highest removal of investigated pharmaceuticals,
415 is confirmed.

416

417 *** Insert Figure 6 here ***

418

419 **Fig. 6:** Removal of pharmaceuticals during control experiments (Exp 6 – Exp 9) compared to
420 removals achieved under optimal working conditions (Exp 10).

421

422

423 3.2 Removal of pharmaceuticals by HC in real WW influent and effluent

424

425 The optimal operating temperature selected during DW experiments ($50 \text{ }^\circ\text{C}$) was used for
426 these experiments. Heating WW prior to HC requires energy, thus raising costs of the
427 treatment process, this energy can, to large extent, be recovered through heat exchangers.
428 In this way not only the costs of the process are significantly reduced, but also the
429 environmental permissible levels on energy dissipation by introducing the treated water into
430 the watercourses can be reached. With fixed operating temperature different cavitation times
431 and H_2O_2 doses were investigated. This course of experiments was selected due to the
432 presence of different organic and inorganic compounds in WW samples, in higher amounts in
433 WW influents and in lower amounts in WW effluents. The hypothesis is that the removal of
434 investigated pharmaceuticals is influenced by these non-target compounds but can be to
435 some extent diminished or even nullified by varying cavitation time and/or H_2O_2 dose. Based
436 on the amount of non-target compounds, more experiments in WW influents were performed
437 with 30 min cavitation time as opposed to WW effluents (15 min), while the H_2O_2 doses
438 investigated were in both cases $0.34, 1.7, 3.4$ and 6.8 g L^{-1} .

439

440 The results obtained for WW influents (see Supplementary data Suppl. 3: Exp A – G)
441 showed different preferences of individual pharmaceuticals regarding operational conditions
442 and give no firm conclusions to which one is more important either cavitation time or H_2O_2
443 addition in their removal. The only exception was CBZ, which was removed almost to the
444 same extent regardless of the operational conditions. During the experiments it was also
445 observed that oxidation of $\text{NH}_4\text{-N}$ to $\text{NO}_3\text{-N}$ becomes more pronounced, when H_2O_2 dose
446 was augmented (see Supplementary data Suppl. 4). The WW influents are very complex
447 matrices consisting of numerous organic and inorganic compounds and cavitation and
448 addition of H_2O_2 can affect, beside pharmaceuticals, non-target compounds forming
449 numerous new species. These can act either as sensitizers or radical scavengers and can
450 influence pharmaceutical removal both positively or negatively, respectively.

451

452 In the case of WW effluents (Table 3: Exp H – N) removal of pharmaceuticals is increased by
453 increasing both cavitation time and H_2O_2 . The highest removal efficiencies (37 to 79 %) were
454 obtained during 30 min cavitation time with 3.4 g L^{-1} of added H_2O_2 (Table 3, Exp N). The
455 same trend is observed for TOC, where the highest removal efficiency was achieved using a
456 cavitation time of 30 min (Table 3, Exp M and N). During these experiments a slight increase

457 in NO₃-N was observed (see Supplementary data Suppl. 4), which was a result of the
 458 oxidation of organic N compounds present in the sample and not NH₄-N which was not
 459 present. By comparing the results obtained for WW effluents to those obtained in DW under
 460 CT (Table 3, Exp K and N) during 15 min of cavitation, in the case of effluent the removal
 461 efficiency is lower, which means that non-target constituents still hinder the removal of
 462 pharmaceuticals which becomes negligible for most pharmaceuticals within 30 min cavitation
 463 time. When compared to the results obtained with Venturi geometry [30] and synthetic
 464 wastewater effluents, the removals of all pharmaceuticals are much higher (from 19 – 48
 465 percentage points) with the same cavitation time and lower H₂O₂ dose.

467 **Table 3**

468 Removal of selected pharmaceuticals by HC in WW effluents under different operational
 469 conditions.

470
 471 *** Insert Table 3 here ***

472
 473 A comparison between removals (%) achieved in WW influents and WW effluents (Exp F and
 474 N) can be made in the case of CLA, IB, CBZ and DF. We see that CLA and CBZ were
 475 removed to the same extent regardless of the matrix, while a matrix effect was more
 476 pronounced in the case of IB and DF. It can be assumed that species that compete for free
 477 radicals and are in higher concentrations present in WW influent inhibit removal of these two
 478 compounds. For NP and KP the removal efficiencies (%) achieved in WW influents and WW
 479 effluents (Exp F and N) cannot be compared in the same way since their concentrations
 480 were much higher in WW influents. Higher initial concentrations of NP and KP result in lower
 481 removal efficiencies (%), but in total a higher amount in nmol is removed after 30 min. This
 482 agrees with the results of other studies [21], [29]. The reasoning behind this is that by
 483 augmenting the amount of the compound in the sample, the probability that it encounters
 484 reactive radicals, responsible for its removal is increased [21], [29]. Based on the physico-
 485 chemical properties of pharmaceuticals (see Supplementary data Suppl. 5), it can be
 486 assumed that the investigated pharmaceuticals are mostly found in the liquid bulk phase and
 487 are not in close proximity of the radicals that mostly appear at the gas-liquid interface. When
 488 the concentration of NP and KP is increased, more molecules can encounter radicals. Thus
 489 the removal efficiency tends to zero, when the concentration of investigated compound falls
 490 below a certain value, since the probability to encounter radicals diminishes. In this case
 491 removal efficiency could be increased by extending the cavitation time.

494 **3.3 Estimation of energy efficiency in WW samples**

495
 496 Economical feasibility i.e., the energy efficiency of investigated HC process was estimated
 497 for WW influents and effluents (see Supplementary data Suppl. 3: Exp. A, C, F; and Table 3:
 498 Exp. H, J, N). It was calculated as the ratio between the amount of the removed
 499 pharmaceuticals and the electrical energy consumed during HC, similar to the method
 500 proposed by Braeutigam and co-workers [21], using Eq.1.

$$502 \quad EE = \frac{\sum Nr}{EC} \quad (1)$$

503
 504
 505 where, EE is the energy efficiency, $\sum Nr$ the amount of pharmaceuticals (nmol) removed from
 506 2.5 L of WW sample during HC experiments and EC is energy consumption (kJ). For
 507 calculation of the EC the sum of power needed to drive the electrical motors (2 x 500 W) and
 508 the circulation pump (80 W) was multiplied by the cavitation time (s). The sum of power
 509 needed to drive the electrical motors was 1.08 kJ s⁻¹.

510

511 **Table 4**

512 Estimation of energy efficiency of the HC process in 2.5 L of WW samples.

513

514 ***** Insert Table 4 here *****

515 Table 4 shows higher amounts of removed pharmaceuticals ($\sum Nr$) in WW influents compared
516 to WW effluents under the same operational conditions. This difference can be attributed to
517 the removal of higher amounts of NP and KP present in considerably higher concentrations
518 (see Supplementary data Suppl. 3) in the WW influents. The highest EE was achieved within
519 5 min cavitation in influent and effluent samples but with the lowest overall removal of
520 pharmaceuticals and/or TOC. For WW influents the highest removal of pharmaceuticals was
521 achieved with 15 min cavitation time and $1.7 \text{ g L}^{-1} \text{ H}_2\text{O}_2$. In the case of WW effluents it can be
522 observed that pharmaceutical and TOC removal increases with prolonged cavitation (from 15
523 to 30 min) at the expense of EE. The highest removal of pharmaceuticals was achieved with
524 a 30 min cavitation time and 3.4 g L^{-1} , which is in accordance with the highest removals
525 presented above (Table 3). Almost the same amounts of pharmaceuticals in WW influents
526 and effluents were obtained during 30 min of cavitation and 3.4 g L^{-1} of H_2O_2 mostly because
527 of higher removals of IB, CBZ and DF in the WW effluents.

528

529

530 **3.4 Removal of pharmaceuticals by HC integrated as a pre- or post-treatment step to** 531 **biological treatment**

532

533 Nowadays, numerous photochemical and chemical advanced treatment techniques (i.e.
534 photolysis, ozonation and AOPs) that could be used to upgrade conventional WW treatment
535 are being investigated. Advanced oxidation processes integrated as a pre-treatment step to
536 biological treatment are generally used for enhancing biodegradability and/or to reduce the
537 toxicity of WW influent, while when integrated as a post-treatment step they serve as a
538 means of removing of bio-recalcitrant compounds [34]. For example, De la Cruz and co-
539 workers [16] investigated the efficiency of direct photolysis (10 min) as a post-treatment step
540 to biological treatment and observed removals of IB, NP, KP, CBZ and DF ranging from 23 –
541 100 % and also reported on their complete removal when they combined UV with the
542 addition of H_2O_2 (50 mg L^{-1} , 30 min). Ternes and co-workers [35] investigated the efficiency
543 of ozonation as a post-treatment step and observed removal efficiencies of >50 % for CLA,
544 IB, NP, CBZ and DF ($10 \text{ mg L}^{-1} \text{ O}_3$, 18 min). Also, high removal efficiencies of the
545 investigated pharmaceuticals were reported for other AOPs (i.e. photo-Fenton process and
546 $\text{O}_3/\text{H}_2\text{O}_2$) when they were used as a post-treatment to biological process [16], [36]. All these
547 techniques have shown great potential to remove pharmaceuticals when used in the post-
548 treatment step. However, in order to fully evaluate their potential and the possibility to
549 incorporate them into WW treatment, more studies are needed and scaled-up experiments
550 are warranted.

551

552 In this study, the aim of was to test the efficiency of HC as a pre- and post-treatment step to
553 biological treatment to improve the overall removal of pharmaceuticals. Attached-growth
554 (biofilm) process was used for biological treatment step. Based on the highest EE
555 determined for WW influents (Table 4), 1.7 g L^{-1} of H_2O_2 and a 15 min cavitation time were
556 used.

557

558 Figure 7 gives a summary of the two experimental setups, i.e. the first is when HC is used as
559 a pre-treatment (PRE) and as post-treatment step (POST) to a biofilm treatment process.
560 Having the results of both setups depicted together, revealed several interesting
561 relationships. First, with the exception of CLA and IB, the PRE setup gives higher removal
562 than the POST setup. Second, when HC was integrated as a pre-treatment, biological
563 removal of pharmaceuticals was smaller than during the POST setup. In the case of CLA and
564 CBZ, no removal was observed during the biological treatment. It was expected that HC will
565 begin to decompose the pharmaceutical residues making them more amenable to biological

566 degradation. The explanation for this surprising outcome may be that the HC actually created
567 degradation products more resistant to biological degradation. Finally, the POST setup, is
568 more efficient at removing CLA and IB, where for IB it seems that the bio step is extremely
569 efficient (90 %). When these results are compared to those achieved using only cavitation
570 (see Supplementary data Suppl. 3) overall removal of IB was increased. Clearly, this study
571 show evidence, for the investigated pharmaceuticals, of distinctive degradation pathways
572 and we thus cannot unanimously give advantage to any of the tested setups.
573

574 During PRE and POST sequence experiments, nitrogen species, TOC, DO and biomass
575 concentration were also measured (see Supplementary data Suppl. 6). In the PRE
576 sequence, chemical oxidation of $\text{NH}_4\text{-N}$ to $\text{NO}_3\text{-N}$ occurred while during the POST sequence,
577 oxidation of $\text{NH}_4\text{-N}$ occurred only during the biological treatment step. The amount of total
578 TOC removed during both sequences was comparable (80 %; see Supplementary data
579 Suppl. 6). When SHC was used as a post-treatment, residual H_2O_2 could affect the
580 consecutive biofilm process. Based on the parameters measured during the biofilm process
581 (see Supplementary data Suppl. 6), H_2O_2 did not affect the biofilm process.
582

583 *** Insert Figure 7 here ***
584

585 **Fig. 7.** Removal of pharmaceuticals with HC integrated as a pre-treatment (PRE) and post-
586 treatment step (POST) to biological step.
587

588 Overall, the results were not as expected. Initially, it was hypothesised that AOP used as a
589 pre-treatment should (without exemption) enhance both removal of recalcitrant target
590 compounds during the HC step and their biodegradability. The results (Figure 7) did not
591 confirm this hypothesis as low removal efficiencies were observed for most test compounds
592 in the second, biological treatment step (exception is IB). Still, significant combined (overall)
593 removals of pharmaceuticals during PRE hydrodynamic cavitation were confirmed (20 – 65
594 %). The overall treatment efficiency of hydrodynamic cavitation and biological treatment
595 show that for NP, KP, CBZ, and DF this combination is better than the POST sequence. The
596 second hypothesis that AOP used as a post-treatment should further enhance removal of
597 bio-recalcitrant compounds was confirmed for all pharmaceuticals. When HC was used as
598 pre-treatment (Figure 7) it yielded higher overall removal efficiencies in case of NP, KP, CBZ
599 and DF and thus for these compounds the pre-treatment sequence is more efficient.
600 Furthermore, based on the TOC results (see Supplementary data Suppl. 6) HC reduces TOC
601 for >45 % in 15 min with addition of 1700 mg L^{-1} of H_2O_2 , whereas, it takes 48 hours to reach
602 >65 % TOC reduction with biological treatment. This information is very important if HC is to
603 be considered as an industrial technology. The results show that HC with the addition of
604 H_2O_2 is worthy of further investigation as a technology applicable for advanced WW
605 treatment.
606

607

608 CONCLUSIONS

609

610 This study reveals that the removal of target organic compounds i.e. pharmaceuticals with
611 hydrodynamic cavitation in different aqueous matrices depends on several parameters. The
612 design of the hydrodynamic cavitation device, operating temperature, cavitation time, H_2O_2
613 dose, matrix composition and chemical properties of the compounds under investigation all
614 play an important role in the removal efficiency. The aggressiveness of hydrodynamic
615 cavitation, which is related to the design of the cavitating device, influences the amount of
616 free radicals formed and consequently the removal efficiency. Shear-induced cavitation,
617 investigated in this study, proved to be more aggressive and led to higher removals of
618 pharmaceuticals in deionised water and real wastewater samples than the cavitation formed
619 using a Venturi constriction. Increasing the operating temperature also proved advantageous
620 for removal but only up to a certain point. A temperature of $50 \text{ }^\circ\text{C}$ was selected as optimal.

621 Cavitation time proved an important operating parameter only in the case of real wastewater
622 samples (30 min) while H₂O₂ addition enhanced the efficiency of cavitation in both deionised
623 water and wastewater effluents (0.34 g L⁻¹ and 3.4 g L⁻¹, respectively). Matrix composition
624 effect on removal efficiency was confirmed for wastewater influents and effluents. Different
625 removal efficiencies under identical operating parameters proved that the individual chemical
626 properties of the compounds also play an important role. Hydrodynamic cavitation is more
627 effective as a pre-treatment step to biological treatment for most investigated
628 pharmaceuticals and was the most pronounced in the case of carbamazepine and
629 diclofenac.

630

631 The continued redesign of the hydrodynamic cavitation device and a better understanding of
632 how different parameters affect the removal of pharmaceuticals will lead to even more
633 efficient treatment process thus making hydrodynamic cavitation worthy of further
634 investigation. Since monitoring of diclofenac, a WFD priority pollutant candidate, in surface
635 waters will likely become obligatory in the near future, one can anticipate that studies
636 investigating improved removal of bio-recalcitrant pharmaceuticals will become very
637 important. Hydrodynamic cavitation and subsequent biological treatment (or vice-versa) may
638 be a good option.

639

640

641 ACKNOWLEDGEMENTS

642

643 This work was financially supported by the Slovenian Research Agency (Program Group P1-
644 0143, Project J7-4265, Project L1-5457 and Slovene-Croatian bilateral project
645 "Determination of toxicity and physico-chemical properties of pharmaceuticals"), Slovenian
646 Technology Agency (Young Researcher in the Economy, Grant P-MR-09/26, Operation is
647 partly financed by the European Union, European Social Fund.). The authors would also like
648 to thank Mr. Željko Blažeka, CEO of the Ecological Engineering Institute Ltd, Maribor,
649 Slovenia, for supporting this research.

650

651

652

653

654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708

REFERENCES

- [1] Proposal for a Directive of the European Parliament and of the Council amending directives 2000/60/EC and 2008/105/EC as regard priority substances in the field of water policy; European Commission, Brussels, 31.1.2012;
http://ec.europa.eu/environment/water/water-dangersub/pdf/com_2011_876.pdf
- [2] Directive 2000/60/EC of the European Parliament and of the Council of 23 October 2000 establishing a framework for Community action in the field of water policy
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:327:0001:0001:EN:PDF>
- [3] Directive 2008/105/EC of the European Parliament and of the Council of 16 December 2008 on environmental quality standards in the field of water policy, amending and subsequently repealing Council Directives 82/176/EEC, 83/513/EEC, 84/156/EEC, 84/491/EEC, 86/280/EEC and amending Directive 2000/60/EC of the European Parliament and of the Council
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:348:0084:0097:EN:PDF>
- [4] T. Kosjek, H. R. Andersen, B. Kompare, A. Ledin, E. Heath, Fate of carbamazepine during water treatment. *Environ. Sci. Technol.* 43 (2009) 6256-6261.
- [5] D. Fatta-Kassinos, S. Meric, A. Nikolaou, Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research, *Anal. Bioanal. Chem.* 399 (2011) 251–275.
- [6] N. Lindqvist, T. Tuhkanen, L. Kronberg, Occurrence of acidic pharmaceuticals in raw and treated sewages and in receiving waters, *Water Res.* 39 (2005) 2219-2228.
- [7] C. Zwiener, F. H. Frimmel, Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibrac acid, ibuprofen, and diclofenac, *Sci. Total Environ.* 309 (2003) 201-211.
- [8] B. Quinn, F. Gagné, C. Blaise, An investigation into the acute and chronic toxicity of eleven pharmaceuticals (and their solvents) found in wastewater effluent on the cnidarians, *Hydra attenuate*, *Sci. Total Environ.* 389 (2008) 306-314.
- [9] B. Ferrari, N. Paxéus, R. Lo Guidice, A. Pollio, J. Garric, Ecotoxicological impact of pharmaceuticals found in treated wastewater: study of carbamazepine, clofibrac acid and diclofenac, *Ecotox. Environ. Safe.* 55 (2003) 359-370.
- [10] L.H.M.H.M. Santos, A.N. Araújo, A. Fachini, A. Pena, C. Delerue - Matos, M.C.B.S.M. Montenegro, Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment, *J. Hazard. Mater.* 175 (2009) 45-95.
- [11] R. Andreozzi, V. Caprio, A. Insola, R. Marotta, Advanced oxidation processes (AOP) for water purification and recovery, *Catal. Today* 53 (1999) 51–59.
- [12] P. R. Gogate, Cavitation: an auxiliary technique in wastewater treatment schemes, *Adv. Environ. Res.* 6 (2002) 335-358.
- [13] P. R. Gogate, A. B. Pandit, A review of imperative technologies for wastewater treatment I: oxidation technologies at ambient conditions, *Adv. Environ. Res.* 8 (2004) 501–551.
- [14] M. Klavarioti, D. Mantzavinos, D. Kassinos, Removal of residual pharmaceuticals from aqueous systems by advanced oxidation processes, *Environ. Int.* 35 (2009) 402–417.
- [15] V. Naddeo, S. Meric, D. Kassinos, V. Belgiorno, M. Guida, Fate of pharmaceuticals in contaminated urban wastewater effluent under ultrasonic irradiation, *Water Res.* 43 (2009) 4019-4027.
- [16] N. De la Cruz, J. Giménez, S. Esplugas, D. Grandjean, L. F. de Alencastro, C. Pulgarín, Degradation of 32 emergent contaminants by UV and neutral photo-fenton in domestic wastewater effluent previously treated by activated sludge, *Water Res.* 46 (2012) 1947-1957.
- [17] S. Esplugas, D. M. Bila, L. G. T. Krause, M. Dezotti, Ozonation and advanced oxidation technologies to remove endocrine disrupting chemicals (EDCs) and pharmaceuticals and personal care products (PPCPs) in water effluents, *J. Hazard. Mater.* 149 (2007) 631–642.

- 709 [18] Y. Benito, S. Arrojo, G. Hauke, P. Vidal, 2005 Hydrodynamic Cavitation as a low-cost
710 AOP for wastewater treatment: preliminary results and a new design approach, WIT trans.
711 Ecol. Envir. 80 (2005) 495-503.
- 712 [19] S. Arrojo, Y. Benito, A theoretical study of hydrodynamic cavitation, Ultrason.
713 Sonochem. 15 (2008) 203-211.
- 714 [20] R. K. Joshi, P. R. Gogate, Degradation of dichlorvos using hydrodynamic cavitation
715 based treatment strategies, Ultrason. Sonochem. 19 (2012) 532–539.
- 716 [21] P. Braeutigam, M. Franke, R. J. Schneider , A. Lehmann , A. Stolle, B. Ondruschka,
717 Degradation of carbamazepine in environmentally relevant concentrations in water by
718 Hydrodynamic-Acoustic-Cavitation (HAC), Water Res. 46 (2012) 2469-2477.
- 719 [22] P. N. Patil, P. R. Gogate, Degradation of methyl parathion using hydrodynamic
720 cavitation: Effect of operating parameters and intensification using additives, Sep. Purif.
721 Technol. 95 (2012) 172–179.
- 722 [23] F. Méndez-Arriaga, R. A. Torres-Palma, C. Pétriera, S. Esplugas, J. Gimenez, C.
723 Pulgarin, Ultrasonic treatment of water contaminated with ibuprofen, Water Res. 42 (2008)
724 4243-4248.
- 725 [24] K. K. Jyoti, A. B. Pandit, Water disinfection by acoustic and hydrodynamic cavitation,
726 Biochem. Eng. J. 7 (2012) 201-213.
- 727 [25] S. S. Save, A. B. Pandit, J. B. Joshi, Use of hydrodynamic cavitation for large scale
728 microbial cell disruption, Food Bioprod. Process. 75 (1997) 41-49.
- 729 [26] M. N. Patil, A. B. Pandit, Cavitation - A novel technique for making stable nano-
730 suspensions, Ultrason. Sonochem. 14 (2007) 519-530.
- 731 [27] P. Braeutigam, Z. - L. Wu, A. Stark, B. Ondruschka, Degradation of BTEX in Aqueous
732 Solution by Hydrodynamic Cavitation, Chem. Eng. Technol. 32 (2009) 745–753.
- 733 [28] Z. - L. Wu, B. Ondruschka, P. Bräutigam, Degradation of Chlorocarbons Driven by
734 Hydrodynamic Cavitation, Chem. Eng. Technol. 30 (2007) 642–648.
- 735 [29] X. Wang, Y. Zhang, Degradation of alachlor in aqueous solution by using hydrodynamic
736 cavitation, J. Hazard. Mater. 161 (2009) 202–207.
- 737 [30] M. Zupanc, T. Kosjek, M. Petkovšek, M. Dular, B. Kompare, B. Širok, Ž. Blažeka, E.
738 Heath, Removal of pharmaceuticals from wastewater by biological processes, hydrodynamic
739 cavitation and UV treatment, Ultrason. Sonochem. 20 (2013) 1104-1112.
- 740 [31] A. Osterman, B. Bachert, B. Širok, M. Dular, Time dependant measurements of
741 cavitation damage, Wear 266 (2009) 945-951.
- 742 [32] M. Petkovšek, M. Zupanc, M. Dular, T. Kosjek, E. Heath, B. Kompare, B. Širok, Rotation
743 generator of hydrodynamic cavitation for water treatment, submitted for publication in
744 Separation and Purification Technology (March 2013)
- 745 [33] C. Vassilakis, A. Pantidou, E. Psillakis, N. Kalogerakis, D. Mantzavinos, Sonolysis of
746 natural phenolic compounds in aqueous solutions: degradation pathways and
747 biodegradability, Water Res. 38 (2004) 3110–3118.
- 748 [34] I. Oller, S. Malato, J.A. Sánchez-Pérez, Combination of Advanced Oxidation Processes
749 and biological treatments for wastewater decontamination – A review, Sci. Total Environ. 409
750 (2010) 4141-4166.
- 751 [35] T. A. Ternes, J. Stüber, N. Herrmann, D. McDowell, A. Reid, M. Kampmann, B. Teiser,
752 Ozonation: A tool for removal of pharmaceuticals, contrast media and musk fragrances from
753 wastewater, Water Res. 37 (2003) 1976-1782.
- 754 [36] R. Rosal, A. Rodriguez, J. A. Perdigón-Melón, M. Mezcuca, M. D. Hernando, P. Letón, E.
755 Garcia-Calvo, A. Agüera, A. R. Fernández-Alba, Removal of pharmaceuticals and kinetics of
756 mineralization by O₃/H₂O₂ in a biotreated municipal wastewater, Water Res. 42 (2008) 3719-
757 3728.
- 758
- 759




Fig. 1. Schematic presentation of the open loop HC set-up (1: feeding reservoir, 2: HCG chamber, 3: control valves, 4: pressure transmitter, 5: centrifugal pump, 6: cooling system, 7: resistance temperature detector).




Fig. 2. Design of the HCG (R1: rotor with 12 grooves, R2: rotor with 11 grooves, A: 0.8 mm gap, EM1: electrical motor, EM2: electrical motor, a: 8° inclination, b: 7 mm depth, c: 10 mm width, B: cavitation zones).




Fig. 3: Removal of pharmaceuticals with increasing temperature (IT) experiments (n = number of experiments).




Fig. 4. Effect of the operating temperature on removal of investigated pharmaceuticals with $3.4 \text{ g L}^{-1} \text{ H}_2\text{O}_2$ dose and 15 min cavitation time ($n =$ number of experiments).




Fig. 5. Effect of H_2O_2 dose on removal efficiency of investigated pharmaceuticals ($1 \mu\text{g L}^{-1}$) with 15 min cavitation time and 50°C (n = number of experiments).




Fig. 6: Removal of pharmaceuticals during control experiments (Exp 6 – Exp 9) compared to removals achieved under optimal working conditions (Exp 10).




Fig. 7. Removal of pharmaceuticals with HC integrated as a pre-treatment (PRE) and post-treatment step (POST) to biological step.

Table 1
Experimental conditions.

variable matrix	HC		
	TEMPERATURE (°C)	CAVITATION TIME (min)	c(H ₂ O ₂) (g L ⁻¹) Exp. No/letter (in brackets)
DW	IT: 20-68	26	0 (1); 3.4 (3); 6.8 (2)
	IT: 20-55	15	3.4 (5); 6.8 (4)
	CT: 40, 50, 60, 68	15	3.4
	CT: 50	5 - 30 (5 min interval)	3.4
WW infl	CT: 50	15	0; 0.17; 0.34; 1.7; 3.4; 6.8
		5	3.4 (A)
		30	1.7 (B); 3.4(C) 0.34 (D); 1.7 (E); 3.4 (F); 6.8 (G)
WW effl	CT: 50	5	3.4 (H)
		15	0.34 (I); 1.7 (J); 3.4 (K); 6.8 (L)
		30	1.7 (M); 3.4 (N)
WW infl	HC → BIOLOGICAL TREATMENT (48 h)		
	CT: 50	15	1.7
WW infl	BIOLOGICAL TREATMENT (48 h) → HC		
	CT: 50	15	1.7

Table 2

Experimental conditions in control experiments.

Exp No.	cavitation	temperature (°C)	H ₂ O ₂ (g L ⁻¹)	time (min)	1-butanol (g L ⁻¹)
Exp 6 ^a	-	50	-	30	-
Exp 7	yes	50	-	15	-
Exp 8 ^a	-	50	6.8	30	-
Exp 9	yes	20	3.4	15	3.3
Exp 10	yes	50	3.4	15	-

^aperformed in a 5 L beaker on a magnetic stirrer

Table 3

Removal of selected pharmaceuticals by HC in WW effluents under different operational conditions.

				concentrations before HC						
				ng L ⁻¹						mg L ⁻¹
				CLA	IB	NP	KP	CBZ	DF	TOC
				1192	1186	981	933	1371	1190	100
				REMOVAL (%)						
effluent	Exp	time (min)	H ₂ O ₂ (g L ⁻¹)							
	H	5	3.4	13	7	45	12	9	36	19
	I	15	0.34	4	0	40	2	1	26	17
	J	15	1.7	10	3	40	9	6	31	37
	K	15	3.4	15/48 ^a	28/60 ^a	44/83 ^a	24/66 ^a	24/72 ^a	45/82 ^a	28
	L	15	6.8	5	11	51	24	12	43	33
	M	30	1.7	18	24	58	30	26	55	53
	N	30	3.4	37/35 ^a	54/60 ^a	74/93 ^a	55/58 ^a	62/70 ^a	79/79 ^a	40

^a removal determined in DW under identical experimental conditions

Table 4

Estimation of energy efficiency of the HC process in 2.5 L of WW samples.

operational conditions			WW influent				WW effluent			
time (min)	H ₂ O ₂ (g L ⁻¹)	EC (kJ)	ΣN_i (nmol)	ΣN_r (nmol)	TOC _r (%)	EE (nmol kJ ⁻¹)	ΣN_i (nmol)	ΣN_r (nmol)	TOC _r (%)	EE (nmol kJ ⁻¹)
15	1.7	927	147	52	59	0.053	73	11	37	0.011
30				43	54	0.022		24	53	0.012
5	3.4	324	147	35	50	0.110	73	14	19	0.042
15		927		46	64	0.047		21	28	0.022
30		1944		47	67	0.024		42	40	0.022

where ΣN_i = sum of amounts (nmol) of all investigated pharmaceuticals in 2.5 L sample before HC; ΣN_r = sum of amounts (nmol) of all investigated pharmaceuticals removed; TOC_r = TOC removal; EE = energy efficiency

760 *Highlights*

761

762

763

764

765

766

767

768

769

770

771

- A novel shear-induced hydrodynamic cavitation is employed to study the removal of pharmaceuticals from wastewaters.
- Removal efficiency when using shear-induced cavitation increases up to 49 percentage points when compared to a cavitating Venturi.
- Removal efficiencies of the investigated pharmaceuticals are up to 86 % in deionised water and up to 79 % in wastewater effluent.
- Hydrodynamic cavitation as a pre-treatment yields higher removal of carbamazepine and diclofenac than when applied as a post-treatment.

ACCEPTED MANUSCRIPT